NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II ...

Ontada®, a leader in real-world oncology data and insights, presents new research findings in an oral presentation at ISPOR Europe 2025.

Orbus Therapeutics, Inc., a private pharmaceutical company, today announced it will present updated results from the Phase 3 ...

Imneskibart will now enter late-stage trials after the drug offered durable tumour shrinkage in NSCLC, melanoma and other ...

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals ...

Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives ...

Akebia Therapeutics shares retreated Monday after the company dropped plans for a Phase 3 clinical trial of its drug Vafseo for certain patients. Shares were trading at $1.66, down 19% and nearing the ...

Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- ...

One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways: IAVI's Lassa vaccine candidate rVSVΔG-LASV-GPC has an acceptable safety profile and ...

Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 9:00 ...

In a licensing deal unveiled Monday, Lyell Immunopharma is kicking in $40 million in cash and almost 2 million of its shares ...